SCHEDULE 13G/A: Morgan Stanley Amends SEC Filing, Disclosing 7.5% Stake in Pulmonx Corp

Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, detailing their beneficial ownership of 7.5% of Pulmonx Corp's common stock as of December 31, 2024.

Summary

• Morgan Stanley, as a parent holding company, reported beneficial ownership of 2,965,195 shares of Pulmonx Corp common stock, representing 7.5% of the class.
• Morgan Stanley Capital Services LLC, a wholly-owned subsidiary of Morgan Stanley, reported beneficial ownership of 2,453,800 shares, representing 6.2% of the class.
• The filing is an Amendment No. 3 to Schedule 13G, indicating an update to previously reported ownership information.
• The securities were acquired and are held in the ordinary course of business and not for the purpose or effect of changing or influencing the control of Pulmonx Corp.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing disclosing beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or outlook. It explicitly states the holdings are for ordinary course of business, not control.

Future Outlook

The document is a beneficial ownership disclosure and does not contain any forward-looking statements or guidance regarding Pulmonx Corp's future performance or outlook.

Industry Context

This filing represents a routine disclosure by a major financial institution, Morgan Stanley, regarding its passive investment stake in Pulmonx Corp, a medical technology company. Such disclosures are standard for institutional investors when their ownership crosses certain thresholds or when they update their holdings, providing transparency on significant shareholder positions within the market.

Stakeholder Impact

• Shareholders are informed of the significant beneficial ownership stake held by Morgan Stanley and its subsidiary, providing transparency on the company's ownership structure.

Key Dates

Keywords

Pulmonx Corp, Morgan Stanley, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing